# A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary Syndrome.

> **NCT06788431** · EARLY_PHASE1 · RECRUITING · sponsor: **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.** · enrollment: 18 (estimated)

## Conditions studied

- Atherosclerosis

## Interventions

- **DRUG:** IMC-001 and Optimal medical treatment
- **DRUG:** IMC-001 placebo and optimal medical treatment

## Key facts

- **NCT ID:** NCT06788431
- **Lead sponsor:** ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-10
- **Primary completion:** 2026-10-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06788431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06788431, "A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary Syndrome.". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06788431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*